Lenalidomide for Newly Diagnosed MM and the Incidence of Second Primary Cancer


Lenalidomide for Newly Diagnosed MM and the Incidence of Second Primary Cancer
Slides from a presentation at ASH 2011 and transcribed comments from a recent interview with Paul G Richardson, MD (1/24/12)

Palumbo A et al. Second primary malignancies in newly diagnosed multiple myeloma patients treated with lenalidomide: Analysis of pooled data in 2459 patients. Proc ASH 2011;Abstract 996.

Dr Richardson is Associate Professor of Medicine at Harvard Medical School and Clinical Director of the Jerome Lipper Center for Multiple Myeloma at Dana-Farber Cancer Institute in Boston, Massachusetts.